Kyntra Bio (KYNB) Financials: History & Chart

Kyntra Bio, Inc.(KYNB)

Biotechnology · San Francisco, CA

$6.02-0.07 (-1.10%)

Delayed quote: Oct 6, 2026, 12:17 PM EDT

About Kyntra Bio, Inc.

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

San Francisco, CA

34 employees

www.kyntrabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Thane Wettig

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	4.62M	-1.47M	3.74M	1.28M	1.08M	1.35M	2.74M	-123.26M	46.33M
Cost of Goods Sold	3.78M	2K	4.11M	-463K	134K	306K	579K	-20.67M	5.29M
Gross Profit	838K	-1.48M	-368K	1.74M	942K	1.04M	2.16M	-102.59M	41.04M
Gross Profit Margin	18.2%	100.1%	-9.8%	136.3%	87.5%	77.3%	78.9%	83.2%	88.6%
Total Operating Expenses	51.67M	16.10M	13.45M	15.81M	6.31M	12.70M	16.95M	-10.93M	57.82M
Research & Development	22.86M	6.82M	7.57M	7.27M	1.21M	5.87M	9.18M	1.49M	21.71M
Selling, General & Administrative	28.22M	9.27M	5.86M	7.99M	5.10M	6.84M	7.78M	-13.32M	17.55M
Operating Income (EBIT)	-50.83M	-17.57M	-13.82M	-14.07M	-5.37M	-11.66M	-14.79M	-91.66M	-16.78M
Operating Margin	-1101.0%	1192.3%	-369.7%	-1102.0%	-499.1%	-864.9%	-540.1%	74.4%	-36.2%
Income Before Tax (EBT)	-30.91M	11.97M	-15.13M	-14.61M	-13.15M	-13.78M	-16.76M	-87.59M	-17.07M
Interest Income	4.99M	N/A	1.11M	2.94M	931K	286K	413K	204K	3.80M
Interest Expense	9.29M	2.37M	2.43M	2.41M	2.08M	2.01M	2.26M	N/A	4.99M
Other Income/Expense	19.92M	29.55M	-1.31M	-537K	-7.78M	-2.12M	-1.97M	4.07M	-294K
Net Income	183.19M	11.97M	-15.20M	37.94M	148.47M	-7.60M	4.64M	17.98M	-17.08M
Income Tax Expense	-1K	-1K	0.00	0.00	0.00	-92K	2K	-52K	12K
Net Profit Margin	3967.8%	-812.3%	-406.6%	2971.3%	13798.6%	-564.0%	169.4%	-14.6%	-36.9%
EBITDA	-50.62M	-17.57M	-13.81M	-14.06M	-5.18M	-11.44M	-14.47M	-91.30M	-16.04M
EBITDA Margin	-1096.4%	1191.9%	-369.5%	-1101.3%	-481.2%	-848.5%	-528.2%	74.1%	-34.6%
Depreciation & Amortization	213K	6K	7K	8K	192K	221K	327K	352K	739K
EPS Basic	N/A	2.96	-3.76	9.38	N/A	-1.88	0.05	4.50	-4.25
EPS Diluted	N/A	2.96	-3.76	9.38	N/A	-1.88	0.05	4.50	-4.25
Weighted Average Basic Shares	4.05M	4.05M	4.05M	4.04M	4.04M	4.04M	4.04M	4.03M	4.02M
Weighted Average Diluted Shares	4.05M	4.05M	4.05M	4.04M	4.04M	4.04M	4.04M	4.03M	4.02M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	6.44M	29.62M	46.80M	140.73M	235.31M	176.32M	256.58M	212.96M
Cost of Goods Sold	556K	15.56M	3.96M	20.28M	449.19M	8.87M	1.15M	235.84M
Gross Profit	5.88M	14.06M	42.84M	120.45M	-213.88M	167.45M	255.43M	-22.88M
Gross Profit Margin	91.4%	47.5%	91.5%	85.6%	-90.9%	95.0%	99.6%	-10.7%
Total Operating Expenses	51.78M	164.48M	365.56M	421.48M	74.65M	359.33M	344.74M	299.65M
Research & Development	23.52M	95.69M	266.47M	296.79M	387.04M	252.92M	209.26M	235.84M
Selling, General & Administrative	27.71M	49.33M	86.48M	124.69M	0.00	106.41M	135.48M	63.81M
Operating Income (EBIT)	-45.90M	-150.42M	-322.72M	-301.02M	-288.53M	-191.88M	-89.31M	-86.69M
Operating Margin	-712.7%	-507.8%	-689.5%	-213.9%	-122.6%	-108.8%	-34.8%	-40.7%
Income Before Tax (EBT)	-58.29M	-153.37M	-323.22M	-293.30M	-289.68M	-188.93M	-76.64M	-86.12M
Interest Income	2.94M	5.30M	7.59M	7.60M	N/A	5.55M	15.55M	11.57M
Interest Expense	8.76M	8.25M	8.10M	1.44M	1.07M	2.40M	2.88M	10.99M
Other Income/Expense	-12.40M	-2.95M	-501K	7.73M	-1.15M	2.95M	12.67M	577K
Net Income	183.45M	-47.58M	-284.23M	-293.65M	-290.02M	-189.29M	-76.97M	-86.42M
Income Tax Expense	-90K	-269K	-252K	358K	347K	360K	328K	304K
Net Profit Margin	2848.6%	-160.6%	-607.3%	-208.7%	-123.3%	-107.4%	-30.0%	-40.6%
EBITDA	-45.15M	-147.72M	-312.79M	-290.42M	-273.72M	-169.83M	-67.86M	-80.13M
EBITDA Margin	-701.0%	-498.7%	-668.3%	-206.4%	-116.3%	-96.3%	-26.4%	-37.6%
Depreciation & Amortization	748K	2.69M	9.93M	10.60M	14.81M	22.05M	21.45M	6.56M
EPS Basic	45.37	-0.48	-2.92	-3.15	-3.15	-2.11	-0.89	-1.03
EPS Diluted	45.37	-0.48	-2.92	-3.15	-3.15	-2.11	-0.89	-1.03
Weighted Average Basic Shares	4.04M	4.00M	3.89M	3.74M	3.69M	3.59M	3.47M	3.36M
Weighted Average Diluted Shares	4.04M	4.00M	3.89M	3.74M	3.69M	3.59M	3.47M	3.36M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.